Jonathan Dokter1, Lauren E Tennyson2, Laura Nguyen3, Esther Han4, Larry T Sirls4,1. 1. Oakland University William Beaumont School of Medicine, Rochester, MI, USA. 2. Department of Urology, Female Pelvic Medicine and Reconstructive Surgery, Beaumont Health, 3535 W. 13 Mile Road, Suite 438, Royal Oak, MI, 48073, USA. Lauren.tennyson@beaumont.org. 3. Department of Urology, McMaster University, Hamilton, ON, Canada. 4. Department of Urology, Female Pelvic Medicine and Reconstructive Surgery, Beaumont Health, 3535 W. 13 Mile Road, Suite 438, Royal Oak, MI, 48073, USA.
Abstract
PURPOSE: To determine the rate of antibiotic change in an outpatient setting following empiric treatment of culture proven UTI and to identify risk factors associated with change. METHODS: Patients with suspected UTI and urine culture were reviewed (January 2016-June 2016). Those with a positive culture were categorized by whether or not they were treated empirically. Empiric treatment was evaluated for associations with clinical-demographic data, symptoms and urinalysis (UA). Antibiotic change was evaluated with clinical-demographic data, urine culture, and resistance patterns. RESULTS: 916 urine cultures (636 patients) were included. 391 (43%) cultures were positive, and 164 (42%) were treated empirically. Clinical-demographic data did not differ between groups. Those treated empirically had more documented UTI symptoms (93 vs 58%, P < 0.001), and UA abnormalities including positive nitrites (51 vs 29%, P < 0.001), 3 + leukocyte esterase (27 vs 19%, P = 0.002) and 3 + blood (13 vs 4%, P = 0.005). Of those treated empirically, 42/164 (26%) required an antibiotic change, and this was associated with immunosuppression (12 vs 2%, P = 0.027) resistance to > 3 antibiotics (33 vs 20%, P = 0.039) and also resistance to fluoroquinolone (50 vs 30%, P = 0.016), monobactam (19 vs 7% P = 0.042) and TMP-SMX (52 vs 19%, P < 0.001). CONCLUSIONS: Almost one-quarter of patients treated empirically required antibiotic change. This was driven largely by bacterial resistance. New technologies allowing rapid bacterial identification and sensitivity may improve patient care.
PURPOSE: To determine the rate of antibiotic change in an outpatient setting following empiric treatment of culture proven UTI and to identify risk factors associated with change. METHODS:Patients with suspected UTI and urine culture were reviewed (January 2016-June 2016). Those with a positive culture were categorized by whether or not they were treated empirically. Empiric treatment was evaluated for associations with clinical-demographic data, symptoms and urinalysis (UA). Antibiotic change was evaluated with clinical-demographic data, urine culture, and resistance patterns. RESULTS: 916 urine cultures (636 patients) were included. 391 (43%) cultures were positive, and 164 (42%) were treated empirically. Clinical-demographic data did not differ between groups. Those treated empirically had more documented UTI symptoms (93 vs 58%, P < 0.001), and UA abnormalities including positive nitrites (51 vs 29%, P < 0.001), 3 + leukocyte esterase (27 vs 19%, P = 0.002) and 3 + blood (13 vs 4%, P = 0.005). Of those treated empirically, 42/164 (26%) required an antibiotic change, and this was associated with immunosuppression (12 vs 2%, P = 0.027) resistance to > 3 antibiotics (33 vs 20%, P = 0.039) and also resistance to fluoroquinolone (50 vs 30%, P = 0.016), monobactam (19 vs 7% P = 0.042) and TMP-SMX (52 vs 19%, P < 0.001). CONCLUSIONS: Almost one-quarter of patients treated empirically required antibiotic change. This was driven largely by bacterial resistance. New technologies allowing rapid bacterial identification and sensitivity may improve patient care.
Authors: Michael Davenport; Kathleen E Mach; Linda M Dairiki Shortliffe; Niaz Banaei; Tza-Huei Wang; Joseph C Liao Journal: Nat Rev Urol Date: 2017-03-01 Impact factor: 14.432
Authors: Leonie G M Giesen; Gráinne Cousins; Borislav D Dimitrov; Floris A van de Laar; Tom Fahey Journal: BMC Fam Pract Date: 2010-10-24 Impact factor: 2.497
Authors: Anne Holm; Gloria Cordoba; Tina Møller Sørensen; Lisbeth Rem Jessen; Niels Frimodt-Møller; Volkert Siersma; Lars Bjerrum Journal: BMJ Open Date: 2017-10-16 Impact factor: 2.692
Authors: Cara L Grimes; Ethan M Balk; Catrina C Crisp; Danielle D Antosh; Miles Murphy; Gabriela E Halder; Peter C Jeppson; Emily E Weber LeBrun; Sonali Raman; Shunaha Kim-Fine; Cheryl Iglesia; Alexis A Dieter; Ladin Yurteri-Kaplan; Gaelen Adam; Kate V Meriwether Journal: Int Urogynecol J Date: 2020-04-27 Impact factor: 2.894